The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy
Abstract
Background Renal function declines progressively in patients who have diabetic nephropathy, and the decline may be slowed by antihypertensive drugs. The purpose of this study was to determine whether captopril has kidney-protecting properties independent of its effect on blood pressure in diabetic nephropathy. Methods We performed a randomized, controlled trial comparing captopril with placebo in patients with insulin-dependent diabetes mellitus in whom urinary protein excretion was > or = 500 mg per day and the serum creatinine concentration was Results Two hundred seven patients received captopril, and 202 placebo. Serum creatinine concentrations doubled in 25 patients in the captopril group, as compared with 43 patients in the placebo group (P = 0.007). The associated reductions in risk of a doubling of the serum creatinine concentration were 48 percent in the captopril group as a whole, 76 percent in the subgroup with a baseline serum creatinine concentration of 2.0 mg per deciliter (177 mumol per liter), 55 percent in the subgroup with a concentration of 1.5 mg per deciliter (133 mumol per liter), and 17 percent in the subgroup with a concentration of 1.0 mg per deciliter (88.4 mumol per liter). The mean (+/- SD) rate of decline in creatinine clearance was 11 +/- 21 percent per year in the captopril group and 17 +/- 20 percent per year in the placebo group (P = 0.03). Among the patients whose base-line serum creatinine concentration was > or = 1.5 mg per deciliter, creat…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [432]
In the citing paper
“In patients with diabetic kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors,3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors,6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone8,9 all reduced the risk of progression to kidney failure.”
From Empagliflozin in Patients with Chronic Kidney Disease (2023) · cites this paper as [5]
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [72]
In the citing paper
“Treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) has been shown to prevent major adverse kidney outcomes in people with diabetes, and these drugs are recommended by clinical practice guidelines for the treatment of people with type 2 diabetes who have, or are at high risk of, kidney disease.[4][5][6][7][8]”
From SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis (2019) · cites this paper as [4]
In the citing paper
“there were suggestions in clinical trials that the greatest slowing of kidney disease progression occurred in patients with the lowest eGFR at study initiation. 33,62”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [33]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344247 · Cited by 2,264
Zatz, R., Dunn, B. R., Meyer, T. W., Anderson, S., Rennke, H. G., & Brenner, B. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112521 · Cited by 1,209
Parving, H.-H., Smidt, U., Andersen, A., & Svendsen, P. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92462-5 · Cited by 867
Pollare, T., Lithell, H., & Berne, C. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909283211305 · Cited by 856
Research works printed but not linked: 3
- Parving H-H, 1985, Hypertension, 7, II
- Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: Iowa State University Press, 1980.
- Fogo A, 1989, Semin Nephrol, 9, 329
Cited by
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Metadata
- Authors
- Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D.
- Affiliations
- Rush University Medical Center (US)
- University of Iowa (US)
- George Washington University (US)
- ORCID
- Lewis, Edmund J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1993-11-11
- Volume
- 329
- Issue
- 20
- Pages
- 1456-1462
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2615684303
- Semantic Scholar
- afd34604099076f4106fd2cd0edd98b29b2cd9a7
- Cited by
- 5,394
- References
- 36
- Citations by year
- 2026: 74 · 2025: 91 · 2024: 81 · 2023: 134 · 2022: 110 · 2021: 97 · 2020: 108 · 2019: 96 · 2018: 98 · 2017: 92 · 2016: 119 · 2015: 127 · 2014: 171 · 2013: 150 · 2012: 161
- FWCI
- 115.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01dk039826-05, 5r01dk039908-05)
- National Institute of Diabetes and Digestive and Kidney Diseases (5 R01-DK 39826, 5 R01-DK 39908)
- National Center for Research Resources (M01RR000030, MO1RR00030)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, captopril, ACE inhibitors, type 1 diabetes, renal protection, serum creatinine doubling, proteinuria, blood pressure control, end-stage renal disease, dialysis, kidney transplantation, mortality, renal function decline, antihypertensive therapy
- MeSH terms
- Adult, Captopril, Creatinine, Diabetic Nephropathies, Double-Blind Method, Female, Follow-Up Studies, Humans, Kidney, Male, Middle Aged, Patient Compliance, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. https://app.cochat.ai/papers/10.1056/nejm199311113292004
- The paper
- Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993). The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. New England Journal of Medicine. https://doi.org/10.1056/nejm199311113292004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.